Optimization of a procedure used to measure aerosol characteristics of nebulized solutions using a cooled next generation impactor. 2010

Ariel Berlinski, and Janet B Hayden
Pulmonology Section, Department of Pediatrics, University of Arkansas for Medical Sciences/COM and Pediatric Aerosol Research Laboratory at ACHRI, Little Rock, Arkansas 72202, USA. BerlinskiAriel@uams.edu

BACKGROUND Cooling the Next Generation Impactor (NGI) is recommended to minimize evaporation due to heat transfer from impactor to aerosols when evaluating nebulized solutions. This methodology increases testing time for serial testing procedures. We hypothesize that after an initial prolonged cooling time, experiments could be repeated after shorter recooling times without sacrificing accuracy. METHODS Three units of continuous output (HUDSON) and breath enhanced (PARI LC Plus) nebulizers were operated (6 L/min) with albuterol solution (2.5 mg/3 mL) into a cooled (4°C) NGI (internal and external filters) calibrated at 15 L/min. Mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), % particles <5 μm (P%<5), and % particles 1-3 μm (P%1-3) were compared with three different protocols. Initial cooling of the NGI (90 min for all protocols) was followed by two measurements with recooling intervals of either 90 and 90 (protocol A), 60 and 60 (protocol B), or 30 and 30 min (protocol C). Albuterol was diluted and measured by spectrophotometry (276 nm). RESULTS MMAD, GSD, P%<5, and P%1-3 for first measurements of all protocols (n = 9) were: 3.47 ± 0.21 μm, 2.31 ± 0.07, 67.3 ± 2.6%, and 40 ± 2.3% (PARI) and 4.56 ± 0.35 μm, 2.16 ± 0.08, 54 ± 3.7%, and 22.4 ± 2.8% (HUDSON). No differences were found between cooling protocols (p > 0.05). Percentage of variation from first measurement ranged from: -3.9 to +2.1% (PARI) and -4.1 to +2.9% (HUDSON) for MMAD; -5.6 to +2.6% (PARI) and -4.9 to +1.9% (HUDSON) for GSD; 0 to +4.6% (PARI) and -3.7% to +5.7% (HUDSON) for P%<5; and -2.4 to +5.2% (PARI) and -1.8 to +4.9% (HUDSON) for P%1-3. CONCLUSIONS Aerosol characteristics of nebulized solutions determined by NGI are not affected by performing two repeat measurements after recooling the impactor for either 30 or 60 min after an initial 90-min time.

UI MeSH Term Description Entries
D009330 Nebulizers and Vaporizers Devices that cause a liquid or solid to be converted into an aerosol (spray) or a vapor. It is used in drug administration by inhalation, humidification of ambient air, and in certain analytical instruments. Atomizers,Inhalation Devices,Inhalators,Inhalers,Vaporizers,Nebulizers,Vaporizers and Nebulizers,Atomizer,Device, Inhalation,Devices, Inhalation,Inhalation Device,Inhalator,Inhaler,Nebulizer,Vaporizer
D010316 Particle Size Relating to the size of solids. Particle Sizes,Size, Particle,Sizes, Particle
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D000336 Aerosols Colloids with a gaseous dispersing phase and either liquid (fog) or solid (smoke) dispersed phase; used in fumigation or in inhalation therapy; may contain propellant agents. Aerosol
D000420 Albuterol A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol. Salbutamol,2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol,Albuterol Sulfate,Proventil,Sultanol,Ventolin
D012996 Solutions The homogeneous mixtures formed by the mixing of a solid, liquid, or gaseous substance (solute) with a liquid (the solvent), from which the dissolved substances can be recovered by physical processes. (From Grant & Hackh's Chemical Dictionary, 5th ed) Solution
D013678 Technology, Pharmaceutical The application of scientific knowledge or technology to pharmacy and the pharmaceutical industry. It includes methods, techniques, and instrumentation in the manufacture, preparation, compounding, dispensing, packaging, and storing of drugs and other preparations used in diagnostic and determinative procedures, and in the treatment of patients. Technology, Pharmacy,Pharmaceutic Technology,Pharmaceutical Technology,Pharmacy Technology,Technology, Pharmaceutic

Related Publications

Ariel Berlinski, and Janet B Hayden
March 2009, Journal of aerosol medicine and pulmonary drug delivery,
Ariel Berlinski, and Janet B Hayden
January 2022, Journal of aerosol medicine and pulmonary drug delivery,
Ariel Berlinski, and Janet B Hayden
May 2002, Pharmaceutical development and technology,
Ariel Berlinski, and Janet B Hayden
January 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine,
Ariel Berlinski, and Janet B Hayden
December 2011, Journal of pharmaceutical sciences,
Ariel Berlinski, and Janet B Hayden
January 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine,
Ariel Berlinski, and Janet B Hayden
January 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine,
Copied contents to your clipboard!